[go: up one dir, main page]

AR069130A1 - Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento - Google Patents

Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento

Info

Publication number
AR069130A1
AR069130A1 ARP080104764A ARP080104764A AR069130A1 AR 069130 A1 AR069130 A1 AR 069130A1 AR P080104764 A ARP080104764 A AR P080104764A AR P080104764 A ARP080104764 A AR P080104764A AR 069130 A1 AR069130 A1 AR 069130A1
Authority
AR
Argentina
Prior art keywords
seq
amino acids
complement
modulate
methods
Prior art date
Application number
ARP080104764A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR069130A1 publication Critical patent/AR069130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Reivindicacion 2: Una molécula de enlace de C3b aislada, la cual comprende una porcion de enlace de antígeno que se enlaza específicamente con un epítopo de C3b, en donde la porcion de enlace de antígeno se enlaza con un epítopo de C3b humana dentro o traslapándose con uno de los siguientes: (a) aminoácidos GEDTVQSLTQG de la SEQ ID NO:1; (b) aminoácidos DEDIIAEENIVSRSEF de la SEQ ID NO:2; (c) aminoácidos IRMNKTVAVRT de la SEQ ID NO:3; (d) aminoácidos SDQVPDTESET de la SEQ ID NO:4; (4) aminoácidos VAQMTED de la SEQ ID NO:5; (f) aminoácidos FVKRAP de la SEQ ID NO:6; (g) aminoácidos KDKNRWEDPGKQLYN de la SEQ ID NO:7; (h) aminoácidos CTRYRGDQDATMS SEQ ID NO:8; o (i) aminoácidos GFAPDTDDLKQLANGV SEQ ID NO:9. Las moléculas de enlace de C3Bb corresponden a anticuerpos humanos o humanizados. Las composiciones farmacéuticas que comprenden moléculas de enlace de componentes de complemento (ej. C3b) son utiles para tratar la degeneracion macular relacionada con la edad.
ARP080104764A 2007-11-02 2008-10-30 Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento AR069130A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98495107P 2007-11-02 2007-11-02

Publications (1)

Publication Number Publication Date
AR069130A1 true AR069130A1 (es) 2009-12-30

Family

ID=40343498

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080104764A AR069130A1 (es) 2007-11-02 2008-10-30 Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento

Country Status (21)

Country Link
US (1) US20090175875A1 (es)
EP (1) EP2207807A2 (es)
JP (1) JP2011503024A (es)
KR (1) KR20100067681A (es)
CN (1) CN101848937A (es)
AR (1) AR069130A1 (es)
AU (1) AU2008320820A1 (es)
CA (1) CA2703911A1 (es)
CL (1) CL2008003241A1 (es)
CO (1) CO6270341A2 (es)
CR (1) CR11361A (es)
EA (1) EA201000717A1 (es)
IL (1) IL204722A0 (es)
MA (1) MA31795B1 (es)
MX (1) MX2010004833A (es)
PE (1) PE20091388A1 (es)
SV (1) SV2010003556A (es)
TN (1) TN2010000169A1 (es)
TW (1) TW200924795A (es)
WO (1) WO2009056631A2 (es)
ZA (1) ZA201002335B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044111B1 (en) 2006-06-21 2014-08-13 MUSC Foundation For Research Development Targeting complement factor h for treatment of diseases
JP5781762B2 (ja) * 2007-08-10 2015-09-24 プロテリックス、インク ユニバーサルｉｉｉ型フィブロネクチン結合ドメインのライブラリ
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
PL2207808T3 (pl) 2007-11-02 2013-11-29 Novartis Ag Ulepszone cząsteczki wiążące się z Nogo-A i ich zastosowania farmaceutyczne
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
ME01699B (me) 2009-07-02 2014-09-20 Musc Found For Res Dev Metode za stimulaciju regeneracije jetre
CN102958535A (zh) 2009-11-05 2013-03-06 亚力史剑桥公司 阵发性夜间血红蛋白尿、溶血性贫血和涉及血管内和血管外溶血的疾病状态的治疗
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
CA2803588A1 (en) 2010-06-22 2011-12-29 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the c3d fragment of complement component 3
EP2646821A4 (en) * 2010-11-29 2015-09-23 Novelmed Therapeutics Inc NEOANTIC BODY FOR THE DIAGNOSIS OF TISSUE INJURY
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
BR112016002435A8 (pt) 2013-08-07 2020-09-29 Alexion Pharma Inc proteínas biomarcadoras da síndrome urêmica hemolítica atípica
WO2015105973A1 (en) * 2014-01-08 2015-07-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
CN108699121B (zh) 2015-12-23 2023-07-04 艾丽法有限责任公司 用于抑制补体激活的多肽
SG10202012243VA (en) 2016-06-14 2021-01-28 Regeneron Pharma Anti-c5 antibodies and uses thereof
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
AU2018383751B2 (en) 2017-12-13 2025-05-08 Regeneron Pharmaceuticals, Inc. Anti-C5 antibody combinations and uses thereof
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
CN118434764A (zh) 2021-12-22 2024-08-02 Cdr生物科技股份有限公司 抗c3抗体及其抗原结合片段及其用于治疗眼疾病的用途
US20240228652A9 (en) * 2022-09-20 2024-07-11 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
AU6397796A (en) * 1995-06-29 1997-01-30 Medical Biology Institute Method for identifying peptides that affect protein-protein interactions and complement-modulating peptides
EP1384079A2 (en) * 2001-05-02 2004-01-28 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of breast cancer
US7042716B2 (en) * 2003-08-25 2006-05-09 Simon John Edward Shearman Ergonomic pull-out computer housing
US20090004183A1 (en) * 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
EP1938104A2 (en) * 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US7327547B1 (en) * 2006-01-20 2008-02-05 Epstein Barry M Circuit element and use thereof
MX2009013082A (es) * 2007-06-07 2010-01-15 Genentech Inc Anticuerpos contra c3b y metodos para la prevencion y el tratamiento de trastornos asociados con el complemento.

Also Published As

Publication number Publication date
CR11361A (es) 2010-06-01
MA31795B1 (fr) 2010-10-01
TW200924795A (en) 2009-06-16
TN2010000169A1 (en) 2011-11-11
PE20091388A1 (es) 2009-09-24
KR20100067681A (ko) 2010-06-21
EA201000717A1 (ru) 2010-12-30
MX2010004833A (es) 2010-05-27
WO2009056631A3 (en) 2009-08-20
US20090175875A1 (en) 2009-07-09
EP2207807A2 (en) 2010-07-21
IL204722A0 (en) 2010-11-30
JP2011503024A (ja) 2011-01-27
WO2009056631A2 (en) 2009-05-07
CA2703911A1 (en) 2009-05-07
CN101848937A (zh) 2010-09-29
SV2010003556A (es) 2011-03-23
CO6270341A2 (es) 2011-04-20
ZA201002335B (en) 2011-02-23
AU2008320820A1 (en) 2009-05-07
CL2008003241A1 (es) 2009-07-31

Similar Documents

Publication Publication Date Title
AR069130A1 (es) Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
ES2689080T3 (es) Anticuerpos que se unen a TL1A y sus usos
PE20190737A1 (es) Anticuerpos anti-cd27
PE20090831A1 (es) Anticuerpo monoclonal
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
PE20081478A1 (es) Anticuerpos cd44
PE20211863A1 (es) Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap
AR062895A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
PE20091382A1 (es) Anticuerpos que se une a il-4 y/o a il-13
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
BR112014001573B8 (pt) Molécula fv ao antígeno multivalente
BR112016030686A2 (pt) anticorpos anti tau humanizados
CO6331370A2 (es) Anticuerpos contra el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
PE20120343A1 (es) Anticuerpo anti-cmet que comprende una region bisagra
AR075504A1 (es) Moleculas de anticuerpos que tienen especificidad para el ox40 humano
PE20060817A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
RU2014109039A (ru) Биспецифические антигенсвязывающие молекулы
CL2018001238A1 (es) Moléculas de unión específicas para asct2 y usos de las mismas
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
NO20083793L (no) Antistoffer mot amyloid-beta peptid
PE20180502A1 (es) Composiciones anti-cgrp y uso de las mismas
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure